Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells

Amy E. Hulme, Z Kelley, Zia Okocha and Thomas J. Hope*

Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Lurie 9-290, 303 E. Superior Ave., Chicago, IL, 60611

Running Head: Capsid mutations differentially affect HIV-1 uncoating

#Address correspondence to Thomas J. Hope, thope@northwestern.edu

Word Count

Abstract- 330

Text- 5693
Abstract

After viral fusion with the cell membrane, the conical capsid of HIV-1 disassembles by a process called uncoating. We recently utilized the CsA washout assay, in which TRIM-CypA mediated restriction of viral replication is used to detect the state of the viral capsid, to study the kinetics of uncoating in HIV-1 infected cells. Here we have extended this analysis to examine the effect of p24\textsuperscript{CA} mutations and cellular environment on the kinetics of uncoating in infected cells. We found that p24\textsuperscript{CA} mutations can significantly increase (A92E), delay (E45A and N74D), or have no effect (G94D) on the rate of uncoating and that these alterations are not due to changes in reverse transcription. Inhibition of reverse transcription delayed uncoating kinetics to a similar extent as wildtype with all the p24\textsuperscript{CA} mutants tested. In addition, we observed differences in uncoating in two cell lines suggesting that cellular environment can differentially impact the disassembly of wildtype and mutant capsids. Collectively, these experiments suggest that viral and cellular factors are important for the process of uncoating. Finally, these data support the model whereby early steps in reverse transcription facilitate HIV-1 uncoating.

Importance

The HIV-1 capsid is a conical shaped structure, composed of the HIV-1 encoded protein p24\textsuperscript{CA}, which contains the viral RNA and other proteins needed for infection. After the virus enters a target cell this capsid must disassemble by a process called uncoating. Uncoating is required for HIV-1 infection to progress, but the details of how this process occurs is not known. In this study we used an in vivo assay to examine the uncoating process in HIV-1 infected cells. We determined that p24\textsuperscript{CA} mutations could increase or decrease the rate of uncoating and that this rate varied in different cell lines. We also found that reverse transcription of the viral RNA
altered the process of uncoating before the p24CA mutations. Collectively, these experiments provide a better understanding of how viral and cellular factors are involved with a poorly understood step in HIV-1 infection.
Introduction

After the HIV-1 viral membrane fuses with the target cell membrane a viral complex is released into the cytoplasm of the cell. In this initial complex the viral RNAs and associated proteins are enclosed by a conical shaped capsid. This capsid is composed of monomers of the viral p24 capsid protein \( \text{p24}^{\text{CA}} \) arranged in a hexameric lattice. At some point, the capsid must disassemble by a process called uncoating to release the reverse transcribing viral genome to integrate into the host cell DNA. Where, when, and how the viral capsid dissociates is poorly defined and a source of contention in the field. While it is clear that uncoating is required for HIV-1 replication, many questions remain about the viral and cellular factors involved with the process and its impact on subsequent steps in viral replication.

Two viral factors that have been shown to influence uncoating are the \( \text{p24}^{\text{CA}} \) protein and the process of reverse transcription. Mutations in \( \text{p24}^{\text{CA}} \) can alter capsid stability and decrease infectivity indicating that overall capsid stability is important for optimal viral replication (1-5). In addition, the correct timing of uncoating is thought to be required for viral replication as \( \text{p24}^{\text{CA}} \) mutants that uncoat more rapidly and mutants that uncoat more slowly than wildtype in vitro both decrease infectivity (1). As many of these \( \text{p24}^{\text{CA}} \) mutants with altered capsid stability also displayed defects in reverse transcription, initially it was thought that uncoating preceded reverse transcription (1). However, reverse transcription products can be detected in viral complexes that contain \( \text{p24}^{\text{CA}} \) protein in the cytoplasm of infected cells (6). Furthermore, integration competent PICs can be generated within intact capsids when infection is restricted by TRIM5 alpha in the presence of proteasome inhibitors (7). Finally, treatment with the reverse transcriptase inhibitor nevirapine delays uncoating in HIV-1 infected cells, indicating that
reverse transcription facilitates the process of uncoating (8, 9). Collectively, these data suggest that there is a complex interplay between these two essential steps in viral replication.

Recently we developed an assay to study uncoating kinetics in HIV-1 infected cells, which is based on experiments performed by Perez Caballero et al. to characterize the restriction factor TRIM-CypA (8, 10, 11). In the CsA washout assay TRIM-CypA is used to detect the presence of intact capsids in infected cells and inhibit their infectivity at various times post-infection. Using this assay we found that the half-life of uncoating occurs within an hour of viral fusion and that reverse transcription facilitates the process of uncoating (8). The CsA washout assay is indirect because it measures viral susceptibility to TRIM-CypA restriction which is mediated by the interaction of TRIM-CypA with a hexameric array of p24CA. However, a similar timing and effect of reverse transcription on uncoating has been confirmed by fluorescence microscopy and biochemical assays that directly detect the loss of p24CA (8, 9, 12, 13). Therefore, while indirect, the CsA washout assay provides a good monitor for the process of uncoating in infected cells.

Here we have extended our initial analysis to examine the effect of p24CA mutations on the kinetics of uncoating. We chose p24CA mutations (E45A, N74D, G89V, P90A, A92E, and G94) that are currently actively studied due to their effects on other aspects of HIV replication, including infection of nondividing cells, utilization of nuclear import pathways, and integration site selection (13-19). Often the effect of these mutations on other steps in viral replication has been proposed to be due to changes in uncoating. However, these mutations also may alter the ability of p24CA to interact with host factors that facilitate these subsequent steps in infection. While some of these mutants have been studied in in vitro uncoating assays, it is important to characterize uncoating in HIV-1 infected cells to differentiate between these two possibilities.
We also test whether cellular environment can differentially impact the uncoating of wildtype and mutant viruses. Finally, we determine the relative contributions of reverse transcription and these p24CA mutations on the process of uncoating.

**Materials and Methods**

*Cell lines, viruses, and pharmaceuticals*

HeLa and 293T cells were obtained from the American Type Culture Collection. OMK cells were a gift from P. Bieniasz. The stable cell line HeLa-TC cell was made using a TRIM-CypA expressing retroviral vector. Cells were maintained at 37°C and 5% CO2 and cultured in Dulbecco’s Modified Eagle Media (Cellgro), 10% fetal bovine serum (Gibco), and 1%

Pen/Strep/Glutamine (Gibco). VSV-g pseudotyped virus was produced by PEI transfection of 293T cells with 12 µg HIV-1 proviral plasmid HIV-GFP or p24CA mutants and 8 µg VSV-g expression plasmid. Virus was harvested 48 hours post-transfection, purified through a 0.45 µm filter, and stored at -80°C until use. Cyclosporine A (Calbiochem) was prepared in ethanol and used at a final concentration of 2.5 µM. Nevirapine (NIH AIDS Research and Reference Reagent Program) was prepared in DMSO and used at a final concentration of 5 µM. Ammonium chloride was prepared in ddH2O and used at a final concentration of 2.5 µM.

**CsA washout assay**

The CsA washout assay has been previously described (8, 10). Briefly, OMK cells, HeLa-TC cells, or the parent HeLa cell line were plated in 96 well dishes with each experimental or control reaction performed on triplicate wells. Cells were spinoculated with VSV-g pseudotyped HIV-GFP or p24CA mutant virus in the presence of CsA and 10 µg/ml polybrene for
1.5 hours at 16°C. The inoculation media was then exchanged for warm media, and CsA was washed out of the zero time point reaction by media exchange. Washout continued at various times post-infection. The negative control was ethanol washout. Two days post-infection cells were harvested with 100 µl trypsin and fixed by addition of 100 µl fix (4:1, 1X PBS:10% formaldehyde). The percentage of GFP positive cells was determined by flow cytometry using the Accuri C6 flow cytometer or BD LSR Fortessa Analyzer, averaged for each triplicate reaction, and standard error was calculated. For experiments in HeLa-TC cells, the percentage of infected cells in the ethanol control was subtracted from the CsA reaction at each washout timepoint to determine the percentage of infected cells over background. The half-life of uncoating was determined by a best fit line through the two data points flanking 50% uncoating and times were averaged from multiple independent experiments. The average half-life of uncoating was compared between wildtype and mutant viruses using a Student’s T test.

Nevirapine addition assay and Viral fusion assay

OMK cells were plated and spinoculated with HIV-GFP or p24CA mutant virus similar to the CsA washout assay. When inoculation media was exchanged for warm media, media containing drug (nevirapine or ammonium chloride) and CsA was added to the zero time point reaction. Drug addition continued in the same manner for various times post-infection. Controls included no treatment and continuous treatment with drug. Cells were harvested and the percentage of GFP positive cells was determined as in the CsA washout assay. For the nevirapine addition assay the data were normalized by setting the GFP positive cells in the DMSO carrier control (no nevirapine treatment) to 100%. The percentage of GFP positive cells at the 6 hour addition time point was compared between wildtype and mutant viruses using a Student’s T test.
For the viral fusion assay, the half-life of fusion was determined using a best fit line between the adjacent data points and times were averaged from three independent experiments.

CsA addition assay

The parent HeLa cell line used to make HeLa-TC cells was plated and spinoculated with HIV-GFP or N74D mutant virus similar to the CsA washout assay. When inoculation media was exchanged for warm media, media containing CsA or the carrier control ethanol was added to the zero time point reaction. CsA or ethanol addition continued in the same manner for various times post-infection. Controls included no CsA treatment and continuous CsA treatment. Cells were harvested and the percentage of GFP positive cells was determined as in the CsA washout assay.

Results

Mutations in p24<sup>CA</sup> affect uncoating kinetics in cultured cells

In order to determine the effect of mutations in p24<sup>CA</sup> on the process of uncoating in HIV-1 infected cells we performed the CsA washout assay with six previously described p24<sup>CA</sup> mutant viruses (8, 10). In this assay uncoating is detected by the action of the cellular protein TRIM-CypA which binds to the viral capsid to restrict infection (20-22). TRIM-CypA belongs to the tripartite motif family (TRIM) family of proteins that can block viral infection (23, 24).

While the exact mechanism is not known, TRIM proteins restrict retroviral infection by binding the incoming viral capsid and then either induce degradation of the capsid to block reverse transcription or block nuclear import (7, 25, 26). While it may sound counterintuitive to use a protein that may induce uncoating to study uncoating, the CsA washout assay is based on the binding of TRIM-CypA to the viral capsid and not the mechanism by which TRIM proteins disrupt the capsid. There are two characteristics of TRIM-CypA binding that allow this factor to
be used in an uncoating assay. First, TRIM-CypA, like all TRIM proteins, binds to the hexameric
array of the p24\textsuperscript{CA} protein in the assembled HIV-1 capsid (20-22, 27). Therefore, TRIM-CypA
should only detect coated viral complexes in cells. Second, the drug cyclosporine A (CsA)
prevents the binding of TRIM-CypA to the viral capsid in a reversible fashion (11, 20, 28, 29).
Therefore, when CsA is removed TRIM-CypA can bind any coated viral complexes and restrict
infection. In contrast, any virus that has uncoated sufficiently to lack an array of p24\textsuperscript{CA} protein
capable of binding TRIM-CypA will be able to escape restriction and infect the cell. These two
characteristics of TRIM-CypA binding allow the kinetics of HIV-1 uncoating to be monitored in
infected cells using timed withdrawal of CsA (8, 10, 11).

For the CsA washout assay owl monkey kidney (OMK) cells that endogenously express
TRIM-CypA were synchronously infected with a wildtype or p24\textsuperscript{CA} mutant GFP reporter virus
in the presence of CsA. CsA was then washed out at various times post-infection by media
exchange. Cells were harvested two days post-infection and flow cytometry was used to
determine the percentage of infected cells at each time point, which is indicative of the
percentage of uncoated virions. The data were normalized by setting the percentage of GFP
positive cells where the curve levels off to 100%, allowing a half-life of uncoating to be
calculated. The uncoating kinetics of each p24\textsuperscript{CA} mutant was examined in parallel with the
wildtype control HIV-GFP. Most of these mutations decrease HIV infectivity, so differing
dilutions of each virus were used to achieve a total infectivity of 30-40% in order to optimally
compare uncoating kinetics.

The first two mutants examined were G89V and P90A. These point mutations are located
in the CypA binding loop and disrupt the ability of TRIM-CypA to bind the capsid (30). Indeed,
when the washout assay was performed with these mutants we did not observe an increase in the
percentage of GFP positive cells over time, unlike the HIV-GFP positive control (Figure 1A). In addition, there is little difference between the CsA washout curve and the carrier control EtOH washout curve for both mutants. Therefore, these two mutants demonstrate that changes in the percentage of GFP positive cells over time in the CsA washout assay is dependent on the ability of TRIM-CypA to bind the viral capsid.

Next, we tested two mutants, E45A and N74D, which have been shown to utilize an alternative nuclear import pathway from wildtype HIV (1, 2, 16). The N74D mutation also alters the integration site preference of HIV (17, 18). In the CsA washout assay, E45A uncoated slower than wildtype and had a significantly greater average half-life of uncoating (124 minutes) compared to HIV-GFP (85 minutes; Figure 1B). N74D mutant virus uncoated slower than wildtype, although it was not as delayed as E45A (Figure 1C). The average half-life of uncoating for N74D (110 minutes) was also significantly increased compared to HIV-GFP (85 minutes; Figure 1C). In our initial analysis of HIV-1 uncoating we identified the p24CA mutation Q63/67A as an additional slow uncoating virus compared to wildtype (8). However, the uncoating of Q63/67A was so delayed that we did not calculate a half-life of uncoating as by 5 hours post-infection only 20% of the virus had uncoated.

Finally, we examined the uncoating kinetics of A92E and G94D mutant viruses. These mutations are located near the cyclophilin A binding loop and do not inhibit CypA binding, but rather alter viral infectivity in response to CsA in a cell-type dependent manner (31-33). Because CypA can still bind the capsid these mutants are proposed to alter the response of the virus to cellular CypA binding. In addition, these mutants are impaired for the ability of HIV to infect nondividing cells, indicating that they may have lost the ability to actively transport into the nucleus (14, 34). In the CsA washout assay A92E uncoated faster than HIV-GFP with a
significantly decreased half-life of uncoating (50 min) compared to wildtype (90 min; Figure 1D). The G94D mutation did not significantly alter the kinetics of uncoating or the average half-life of uncoating (90 min) compared to HIV-GFP (97 min; Figure 1E).

**Reverse transcription does not account for the changes in uncoating kinetics**

We previously used the CsA washout assay to determine that reverse transcription facilitates the process of uncoating in cells (8). Therefore it is possible that the changes in uncoating kinetics of these viruses may be due to alterations in reverse transcription. To examine completion of reverse transcription for each mutant virus over time in OMK cells, we performed an addition assay with the non-nucleoside reverse transcriptase inhibitor nevirapine. Using the same experimental conditions as in the CsA washout assay, OMK cells were synchronously infected with wildtype or p24CA mutant GFP reporter virus. Nevirapine was then added at times corresponding to those used in the CsA washout assay. Cells were harvested two days post-infection and the percentage infected cells was determined at each time point of nevirapine addition. These data were normalized by setting the percentage of GFP positive cells in the DMSO carrier control to 100%. Of all the p24CA mutants examined, only E45A showed a correlation between uncoating kinetics and reverse transcription, but this delay in reverse transcription was not statistically significant (Figures 1 and 2). N74D and A92E seemed to reverse transcribe at a rate similar to wildtype, which is not consistent with uncoating slower and faster, respectively, than wildtype (Figures 1 and 2). G94D showed the most delayed completion of reverse transcription of all the mutants tested, which was not statistically significant, but this mutation did not alter uncoating kinetics. We have also previously observed a disparity in the kinetics of completion of reverse transcription and uncoating with the Q63/67A virus. This
p24\textsuperscript{CA} mutant reverse transcribed at a similar rate to wildtype, but displayed much delayed uncoating (8). Therefore, these data suggest that while reverse transcription may facilitate uncoating there are other factors involved with the process.

To determine the hierarchy between reverse transcription and the p24\textsuperscript{CA} mutations on the process of uncoating we examined the effect of reverse transcription on the uncoating kinetics of the p24\textsuperscript{CA} mutant viruses. The CsA washout assay was conducted with and without a two hour nevirapine treatment with HIV-GFP and each p24\textsuperscript{CA} mutant. Treatment with nevirapine shifted the washout assay curves of all mutants similar to that observed with wildtype (Figure 3).

Interestingly, all viruses displayed the same rapid increase in the percentage of GFP positive cells in the hour after nevirapine removal. Therefore, inhibition of reverse transcription has a dominant effect on uncoating compared to the p24\textsuperscript{CA} mutations.

**Cellular milieu can impact uncoating kinetics**

We do not know to what extent cellular environment affects uncoating in vivo. Currently, the favored hypothesis is that cellular factors are involved with facilitating the process of uncoating, but a bona fide uncoating factor has not been identified. In order to examine the effect of cellular environment on uncoating kinetics we conducted the CsA washout assay in a HeLa cell line that was engineered to express TRIM-CypA (HeLa-TC). This assay should also reveal any differences in uncoating between owl monkey cells and human cells, a more relevant cell line with regard to HIV infection.

In parallel CsA washout assays HIV-GFP uncoated significantly faster in HeLa-TC cells compared to OMK cells (Figure 4). We have previously shown that changes in the rate of viral fusion can account for alterations in the observed half-life of uncoating in the CsA washout assay.
Therefore, we performed an ammonium chloride addition assay in both cell lines in parallel with a CsA washout assay to directly correlate the timing of viral fusion and uncoating. Similar to the nevirapine addition assay, cells were infected with GFP reporter virus and then ammonium chloride was added at various times post-infection to block viral fusion. The half-life of viral fusion was greater in HeLa-TC cells compared to OMK cells indicating that the difference in uncoating kinetics between the two cell lines is not due to differences in viral fusion (Figure 4, Table 1). We also examined the uncoating kinetics of N74D virus in both cell lines as this virus has been the most well studied for its differential interaction with cellular host factors (16-19, 35). Similar to OMK cells, N74D uncoated slower than wildtype in HeLa-TC cells (Figure 4). However, the delay in uncoating in HeLa-TC cells was significantly greater than that observed in OMK cells. Collectively, these results suggest that the cellular environment of HeLa-TC cells has a differential effect on the uncoating of HIV-GFP and N74D. As both viruses were pseudotyped with VSV-g it is unlikely that this discrepancy is due to differences in viral fusion.

One potential confounding factor in the assay is that the cellular protein CypA that binds p24 CA. The role of CypA in HIV-1 replication is not well understood as CypA can increase, decrease, or have no effect on viral infectivity depending on cell type (30, 36-38). In the CsA washout assay, the presence of CsA will also prevent the binding of cellular CypA. Therefore, observations made about uncoating using the CsA washout assay will not reveal the effect of cellular CypA, if any, on uncoating. However, it has been shown that the N74D mutation may affect the susceptibility of HIV-1 to cellular CypA in HeLa cells (39). Specifically, blocking CypA binding with CsA decreased infectivity of N74D virus by ~2-3-fold in HeLa cells, whereas wildtype infectivity was slightly increased. We normalize data in the CsA washout assay using the 4 or 5 hour time point independently for each virus. If cellular CypA has a
differential effect on infectivity over time, normalizing the data using the 5 hour timepoint of CsA washout could bias the resultant uncoating curves for each virus. To directly examine the effect of cellular CypA over time on wildtype and N74D mutant virus, we performed a CsA washout assay in the parent HeLa cell line that was used to generate the HeLa-TC cell line (Figure 4D). Ethanol washout was the negative control. The presence of CsA subtly increased HIV-GFP infectivity compared to the ethanol control and this increase was of a similar magnitude at each timepoint examined. For N74D, the presence of CsA decreased infectivity by 2-fold. Importantly, this decrease in infectivity was consistent at each timepoint tested. Therefore, using the 5 hour timepoint to normalize data in the CsA washout assay data will not bias the resultant uncoating kinetics of either HIV-GFP or N74D virus.

The differences between the CsA and ethanol washout curves were consistent over time, suggesting that cellular CypA may not affect uncoating of N74D or HIV-GFP virus in HeLa cells. To more directly address this idea, we performed a CsA addition assay in the parent HeLa cell line, reasoning that if CypA affected uncoating, the virus would escape from the inhibitory effect of CsA with similar kinetics to that of the uncoating (Figure 4E). CsA addition did not affect HIV-GFP infectivity compared to the ethanol control at any timepoint tested. In contrast, N74D virus escaped the inhibitory effects of CsA by 4 hours post-infection when compared to the ethanol control. This gradual increase in infectivity is not similar to the uncoating kinetics as assayed in the CsA washout assay (Figure 4A), suggesting that CypA is not involved in uncoating of N74D virus. Instead, these data suggest that some aspect of the N74D capsid changes by 4 hours post-infection so that it is no longer susceptible to the effects of CypA binding. Given that N74D has been shown to utilize an alternate set of nuclear import factors, it...
is intriguing to speculate that the role of capsid in nuclear import of N74D mutant virus may be different from wildtype.

Discussion

Using the CsA washout assay we were able to observe the effect of p24CA mutations on uncoating kinetics in HIV-1 infected cells (Figure 1). In general there was an approximate 1.5-2 fold difference in the half-life of uncoating for the E45A, N74D, and A92E mutant viruses compared to wildtype. While this difference may be thought of as small, this alteration in uncoating is sufficient to decrease overall infectivity of the virus (1, 2, 14, 39). Interestingly, the two p24CA mutants with the largest alterations in uncoating, E45A and Q63/67A, display greatest defects in infectivity at 3-4% of wildtype (1, 2, 8). The processivity of the HIV-1 RT is 2-3 nucleotides per second, so changes in uncoating rates of as little as 10 of minutes would correlate with very different states (on the order of 1.2 kb) of the reverse transcribing genome. Given the complex interplay between uncoating and reverse transcription, these changes in uncoating could therefore lead to decreased infectivity. The CsA washout assay is also based on infectivity. Therefore, the effect of each mutation on uncoating is likely more severe than the data indicate as a positive readout in the CsA washout assay requires that the virus uncoat and establish a provirus from which to express the GFP reporter. Thus, these mutants also provide a measure of the extent to which HIV can tolerate changes in uncoating and still achieve productive infection.

As expected G89V and P90A did not display a change in GFP positive cells over time due to the fact that these mutations disrupt CypA binding (30). In addition to serving as controls, these mutants show that the increase in infectivity seen over time in the assay is dependent on the ability of TRIM-CypA to bind the retroviral capsid. E45A has previously been shown to have
increased capsid stability and uncoat slower than wildtype in an in vitro assay (1). Our results are consistent with these data as we observed a slower rate of uncoating for E45A. In contrast, N74D does not alter capsid stability and uncoats similar to wildtype in an in vitro assay (35). However, in the CsA washout assay this mutant uncoated slower than wildtype. Additionally, A92E displays similar capsid stability to wildtype, but uncoats faster in the CsA washout assay (14). While there is often a general correlation between in vitro capsid stability and the rate of uncoating, these data suggest that other factors are involved with uncoating in vivo. A similar conclusion was reached in a recent study in which the R132K suppressor mutation of E45A rescued infectivity, but did not restore capsid stability (40). Likewise, we previously reported the Q63/67A p24CA mutation results in slow uncoating kinetics in the CsA washout assay while showing decreased capsid stability and accelerated uncoating kinetics in an in vitro assay (1, 8).

Why are there discrepancies between different uncoating assays? Depending on the methods used each assay may detect a different aspect of the uncoating process. Furthermore, it is not surprising that some mutants may display a different effect on uncoating when assayed using in vivo compared to in vitro assays given that the HIV-1 capsid is relatively difficult to isolate and inherently unstable. For in vitro uncoating assays viral capsids are purified, incubated, and then uncoating is determined by comparing the relative amounts of particulate and soluble p24CA protein (1, 41). In the cell-based fate of the capsid assay infected cells are lysed several hours post-infection and uncoating is assayed by comparing the amounts of particulate and soluble forms of p24CA (42). Coated viral particles can be directly detected in the cytoplasm of infected cells by staining with an antibody to p24CA in microscopy-based uncoating assays (8, 13, 43). Differing from these assays, the CsA washout uses infectivity as a readout and thus is indirect as it measures viral susceptibility to TRIM-CypA. However, the timing of the
loss of sensitivity to TRIM-CypA restriction in the CsA washout assay correlates with the loss of p24CA in infected cells as assayed by fluorescence microscopy and western blot (8, 12, 13). In addition, the delay in uncoating due to inhibition of reverse transcription, first identified with the CsA washout assay and a microscopy assay, has also been confirmed biochemically by western blot (8, 9). Therefore, despite an indirect detection method, the CsA washout assay is a good monitor for the process of uncoating in infected cells.

The CsA washout assay provides a direct correlation between uncoating and infectivity. Because of this, the effect of a mutation on uncoating in the CsA washout assay will only be detected in the subset of viral particles that can achieve productive infection. In the other uncoating assays outlined above viral capsids are analyzed irrespective of their ability to infect cells. As the majority of HIV virions that enter cells do not establish productive infection, the characteristics of these uninfectious virions could account for some of the differences observed between assays. These differences highlight the importance of determining the uncoating kinetics of important p24CA mutants in infected cells and with respect to viral infectivity.

Do changes in uncoating kinetics account for the effect of the p24CA mutations on other steps of HIV-1 replication? Mutations in p24CA have been shown to influence infection of nondividing cells, utilization of nuclear import pathways, and integration site selection (13-19). The E45A, Q63/67A, and N74D mutations all decrease the rate of uncoating to different degrees with N74D the most similar to wildtype and Q63/67A the most delayed (Figure 1; (8)). These mutants also all utilize an alternative nuclear import pathway from TNPO3 and NUP358/RanBP2 which has been implicated in facilitating wildtype HIV-1 nuclear entry (16, 17). Thus, it is tempting to speculate that the rate of uncoating may affect which nuclear import pathway HIV uses during infection. In contrast, A92E and G94D are impaired for infection in
nondividing cells in a CypA dependent manner (14, 34). As only A92E uncoats at a different rate than wildtype, it seems unlikely that the inability of these mutants to infect of nondividing cells is due to an altered rate of uncoating.

While our data suggest that reverse transcription facilitates uncoating, for any of the p24CA mutant viruses there was not a significant difference in reverse transcription that could account for a change in uncoating kinetics ((8); Figure 2). This result further reinforces the conclusion that other factors, likely both viral and cellular, are involved in the uncoating process.

The importance of cellular factors in uncoating is demonstrated by the experiments in the HeLa-TC cells (Figure 4). Despite a slower rate of viral fusion, uncoating of wildtype virus is faster in HeLa-TC cells (Figure 4, Table 1). This could potentially be due to a factor that facilitates uncoating in more abundance in HeLa-TC cells compared to OMK cells or the absence of a factor that abrogates uncoating in HeLa-TC cells. Further experiments would be required to identify such a factor, but these results are important to consider when choosing time points to assay uncoating in different cell types. Furthermore, there was a more pronounced delay in uncoating due to the N74D mutation in HeLa-TC cells compared to OMK cells. This is delay is even more profound when considering that uncoating of wildtype virus is faster in HeLa-TC cells. Interestingly, these results suggest that the cellular environment of HeLa-TC cells has a differential effect on uncoating by facilitating more rapid uncoating of HIV-GFP and more delayed uncoating of N74D. Given that N74D has been shown to utilize a different set of host factors for nuclear entry than wildtype virus it is tempting to speculate that these host factors may be involved with the differential effect in HeLa-TC cells.

The simplest hypothesis is that expression levels of the TRIM-CypA protein account for the differences in uncoating kinetics between OMK and HeLa-TC cells. However, the data do
not support this explanation in two ways. First, in both cell lines the CsA washout assay was conducted under conditions in which TRIM-CypA restriction is not saturated, meaning that in the absence of CsA viral infectivity is completely inhibited. TRIM proteins rapidly associate with incoming virus (11). Therefore, under non-saturating conditions there is a sufficient amount TRIM-CypA protein in both cell lines to bind to the viral capsid and inhibit infectivity. Any additional amount of TRIM-CypA protein present in the cells therefore becomes essentially irrelevant for restriction. Second, if different levels of TRIM-CypA expression were responsible for the altered uncoating kinetics observed in HeLa-TC cells compared to OMK cells, then both viruses should display the same shift in uncoating kinetics. This is not what we observed.

Instead, wildtype virus uncoated faster in HeLa-TC cells while N74D virus uncoated slower (Figure 4A). Therefore, overall differences in TRIM-CypA protein levels between HeLa-TC and OMK cells do not account for the differences observed in the uncoating of wildtype and N74D mutant viruses.

A second hypothesis is that the cellular protein CypA is responsible for the differential uncoating kinetics observed between OMK and HeLa cells. The use of CsA in the assay, which is necessary to regulate TRIM-CypA binding, will also prevent the binding of cellular Cyclophilin A (CypA). The effect of CypA on HIV-1 infectivity is highly cell type specific and the role of CypA in uncoating is not defined (30, 36-38). CypA was able to modulate uncoating in a cell type dependent manner in the fate of the capsid assay and stabilize the capsid in an in vitro uncoating assay (35, 44). In the washout assay observations made about uncoating are irrespective of any effect of cellular CypA on uncoating due to the presence of CsA. It was previously shown that CsA treatment decreased infectivity of N74D virus by ~2-3-fold in HeLa cells, whereas wildtype infectivity was slightly increased (39). Given that we normalize data in
the CsA washout assay using infectivity at the 4 or 5 hour time point, this cell type specific
alternation in infectivity could bias results if the effect of cellular CypA on infectivity changes
over time. However, we found that the increase in HIV-GFP infectivity and decrease in N74D
infectivity was consistent at all timepoints examined in the parent HeLa cell line (Figure 4D).
Therefore, using the 5 hour timepoint to normalize data in the CsA washout assay data will not
bias the resultant uncoating kinetics of either HIV-GFP or N74D virus. Collectively, these results
suggest that cell specific effects of CypA do not account for the differential uncoating kinetics of
HIV-GFP and N74D mutant viruses in HeLa cells compared to OMK cells.

What stage of uncoating is detected in the CsA washout assay? This question is difficult
to answer as the exact mechanism of TRIM protein restriction is not completely defined. The
current model is that TRIM forms a lattice or net around the capsid. This model is based on
electron microscopy experiments in which recombinant TRIM5-21R associated in a hexagonal
lattice over a hexagonal array of p24CA (27). TRIM-CypA would be expected to form a similar
lattice given its high degree of similarity in the coiled-coil and B-Box 2 domains required for
lattice formation (20, 27). Despite this model we do not know how much of the viral capsid is
required to be present for TRIM-CypA lattice formation and restriction. TRIM-CypA can inhibit
the infectivity of virus with mixed capsids in which only 25% of p24CA monomers are
susceptible to restriction (45). However, in these experiments viral capsids were exposed to
TRIM-CypA upon viral entry and therefore were likely intact. A different situation exists in the
CsA washout assay where viral capsids are allowed to uncoat to varying extents in the cytoplasm
before being exposed to TRIM-CypA binding by the withdrawal of CsA. A microscopy assay
that examined the integrity of viral capsids localizing with rhesus TRIM5α cytoplasmic bodies
suggested that TRIM proteins associate with intact capsids (46). Based on this data we
hypothesize that in the CsA washout assay TRIM-CypA is binding intact capsids or viral complexes that have just started to uncoat. Further development of the assay is needed to test this hypothesis, but this would suggest that the CsA washout assay is detecting early stages of HIV uncoating.

We do not know how the process of uncoating occurs, but the data presented here indicate that viral and cellular factors are important. In our current model, the process of reverse transcription facilitates HIV-1 uncoating in the cytoplasm of infected cells. In order to refine this model we examined the effect of reverse transcription on the uncoating of each p24\textsuperscript{CA} mutant. Strikingly, wildtype and p24\textsuperscript{CA} mutant viruses displayed a similar delay in uncoating, suggesting that the effect of reverse transcription on uncoating is functionally active before the effect of the p24\textsuperscript{CA} mutation (Figure 3). In these experiments there was also a rapid increase in the percentage of GFP positive cells in the hour after nevirapine removal for wildtype and p24\textsuperscript{CA} mutant viruses (Figure 3; (8)). This result indicates that a reverse transcription product generated in the hour after nevirapine removal is facilitating uncoating. Using quantitative PCR analysis we previously found that in early products of reverse transcription correlated were generated in the first two hours after viral fusion which correlates with the timing of uncoating in the CsA washout assay (8). In addition, in the CsA washout assay the majority of uncoating occurs by three hours post-infection which precedes the completion of reverse transcription (Figures 1 and 2; (8)). Therefore, these data further support a model in which early steps of reverse transcription facilitate HIV-1 uncoating.

Acknowledgements
We would like to thank Dr. Paul Bieniasz and Dr. Theodora Hatziioannou for OMK cells and Dr. Chris Aiken for proviral plasmids. We also thank the NIH AIDS Research and Reference Reagent Program for nevirapine. We thank the RHLCC flow cytometry core, supported by the Northwestern University Flow Cytometry Core Facility and Cancer Center Support Grant (NCI CA060553). We also thank Dr. Cindy Danielson for critical review of this manuscript. This work was supported by NIH grants RO1 AI47770 and P50 GM082545 to TJH, and 5F32AI089359-03 to AEH.
References


**Figure Legends**

**Figure 1- p24\textsuperscript{CA} mutations affect the observed rate of uncoating.** The CsA washout assay was performed with HIV-GFP and several p24\textsuperscript{CA} mutant viruses. Line graphs are from a representative washout assay. Bar graphs compare the average half-life of uncoating between HIV-GFP and the p24\textsuperscript{CA} mutant virus from multiple independent experiments. Error bars denote standard error. * = p<0.05, ** = p<0.005, *** = p<0.0001

A) Uncoating cannot be observed with G89V and P90A mutant viruses as the mutations make capsid resistant to CypA binding. B) The E45A mutation significantly decreases the rate of uncoating compared to wildtype as measured in 9 independent experiments. C) The N74D mutation significantly decreases the rate of uncoating compared to wildtype as measured in 6 independent experiments. D) The A92E mutation significantly increases the rate of uncoating compared to wildtype as measured in 7 independent experiments. E) The G94D mutation does not significantly alter the rate of uncoating compared to wildtype as measured in 7 independent experiments.

**Figure 2- Progression of reverse transcription for HIV-GFP and P24\textsuperscript{CA} mutant viruses.** A nevirapine addition assay was conducted to monitor completion of reverse transcription for HIV-GFP and each of the p24\textsuperscript{CA} mutant viruses. Data was normalized by setting the DMSO carrier control, to 100%. Shown is the average of three independent experiments. Error bars denote standard error. A) The E45A and G94D mutations subtly decrease the rate of reverse transcription, but this change is not statistically significant at the 6 hour time point. The A92E mutation does not significantly alter completion of reverse transcription relative to wildtype as assayed at the 6 hour time point. B) The N74D mutation does not significantly alter completion of reverse transcription relative to wildtype as assayed at the 6 hour time point.
Figure 3- Inhibition of reverse transcription delays the uncoating of $p24^{CA}$ mutant viruses.

The CsA washout assay was performed with and without a two hour nevirapine treatment for HIV-GFP and each of the $p24^{CA}$ mutant viruses. Shown is a representative assay from three independent experiments. Error bars denote standard error. Inhibition of reverse transcription similarly delays the uncoating kinetics of HIV-GFP, E45A, N74D, A92E, and G94D despite their differential rates of uncoating without nevirapine treatment.

Figure 4- Cellular factors differentially affect uncoating. A) The CsA washout assay was performed with HIV-GFP and N74D virus in OMK and HeLa-TC cells. HIV-GFP uncoats faster in HeLa-TC cells than in OMK cells. The uncoating of N74D is delayed to greater extent in HeLa-TC cells than in OMK cells when compared to wildtype. Shown is a representative washout assay. Error bars denoted standard error. B) The average half-life of uncoating for each virus in each cell type was determined from 4 independent experiments. There is a significant difference in uncoating half-life for HIV-GFP in OMK cells and HeLa-TC cells. There is also a significant difference in the increased half-life of uncoating due to the N74D mutation between OMK cells and HeLa-TC cells. Error bars denote standard error. * = p< 0.05, ** = p<0.005 C).

An ammonium chloride addition assay was performed in parallel with a CsA washout assay to determine the kinetics of viral fusion in relation to uncoating in OMK and HeLa-TC cells. VSV-pseudotyped viruses fused faster in OMK cells compared to HeLa-TC cells. Shown is a representative assay. Error bars denote standard error. D) To determine the effect of CsA on viral infectivity over time in HeLa cells, the CsA washout assay was performed in the parent HeLa cells line for HIV-GFP and N74D viruses. Ethanol washout was the negative control.

Compared to the ethanol control, CsA subtly increases HIV-GFP infectivity at each timepoint.
assayed. Compared to the ethanol control, CsA decreases N74D infectivity with similar magnitude at each timepoint assayed. Shown is a representative experiment from 3 independent experiments. Error bars denote standard error. E). To determine the susceptibility of HIV-GFP and N74D viruses to CsA over time, a CsA addition assay was performed in HeLa cells. Ethanol addition was the negative control. HIV-GFP does not show a change in infectivity over any time of CsA addition. Compared to the ethanol control, N74D virus loses susceptibility to CsA addition between 1 and 4 hours post-infection. Shown is a representative experiment from 3 independent experiments. Error bars denote standard error.

Table 1- Viral fusion impacts the observed rate of uncoating. The CsA washout assay was performed with HIV-GFP in OMK and HeLa-TC cells in parallel with an ammonium chloride addition assay to monitor viral fusion. The average half-lives of uncoating and viral fusion were determined from 3 independent experiments. Standard error is in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>OMK</th>
<th>HeLa-TC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncoating</td>
<td>63.79 (9.48)</td>
<td>36.79 (1.96)</td>
</tr>
<tr>
<td>Fusion</td>
<td>18.8 (1.78)</td>
<td>28.38 (0.62)</td>
</tr>
</tbody>
</table>
**Figure 1**

(A) Graph showing the percentage of GFP-positive cells over time following CsA washout. Different strains and treatments are indicated by different line styles and colors. The x-axis represents time post-infection (hr), while the y-axis represents % Total GFP positive cells.

(B) Graph comparing the uncoating half-life of HIV-GFP and E45A. The x-axis represents time post-infection (hr), and the y-axis represents time (min). The uncoating half-life is shorter for E45A compared to HIV-GFP.

(C) Graph showing the uncoating half-life of HIV-GFP and N74D. Similar to (B), the x-axis represents time post-infection (hr), and the y-axis represents time (min). The uncoating half-life is shorter for N74D compared to HIV-GFP.
Figure 1

D

% Total GFP positive cells

Time PI of CsA washout (hr)

HIV-GFP

A92E

G94D

E

% Total GFP positive cells

Time PI of CsA washout (hr)

HIV-GFP

G94D

Avg uncoating half-life (min)

***

0

20

40

60

80

100

120

0

1

2

3

4

5

Avg uncoating half-life (min)

A92E

HIV-GFP

G94D

HIV-GFP

D

E
Figure 2

A

![Graph A]

B

![Graph B]
Figure 3

A

% Total GFP positive cells
Time PI of CsA washout (hr)

HIV-GFP
HIV-GFP+Nev
N74D
N74D+Nev
E45A
E45A+Nev

B

% Total GFP positive cells
Time PI of CsA washout (hr)

HIV-GFP
HIV-GFP+Nev
A92E
A92E+Nev
G94D
G94D+Nev
Figure 4

A

% Total GFP positive cells vs. Time PI of CsA washout (hr)

- HIV-GFP OMK
- N74D OMK
- HIV-GFP HeLa-TC
- N74D HeLa-TC

B

Avg uncoating half-life (min) vs. OMK or HeLa-TC

- HIV-GFP
- N74D

C

% Total Fusion vs. Time PI of NH4Cl addition (hr)

- OMK
- HeLa-TC
Figure 4

D

E

HIV-GFP CsA wash
N74D CsA wash
HIV-GFP EtOH wash
N74D EtOH wash

HIV-GFP CsA add
N74D CsA add
HIV-GFP EtOH add
N74D EtOH add